Selection of biologically active peptides by phage display of random peptide libraries. 1996

R Cortese, and P Monaci, and A Luzzago, and C Santini, and F Bartoli, and I Cortese, and P Fortugno, and G Galfrè, and A Nicosia, and F Felici
Istituto di Ricerche di Biologia Molecolare P. Angeletti, Via Pontina km 30.600, 00040 Pomezia (Roma), Italy. cortese@irbm.it

Random peptide libraries displayed on phage are used as a source of peptides for epitope mapping, for the identification of critical amino acids responsible for protein-protein interactions and as leads for the discovery of new therapeutics. Efficient and simple procedures have been devised to select peptides binding to purified proteins, to monoclonal and polyclonal antibodies and to cell surfaces in vivo and in vitro.

UI MeSH Term Description Entries
D009928 Organ Specificity Characteristic restricted to a particular organ of the body, such as a cell type, metabolic response or expression of a particular protein or antigen. Tissue Specificity,Organ Specificities,Specificities, Organ,Specificities, Tissue,Specificity, Organ,Specificity, Tissue,Tissue Specificities
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D004353 Drug Evaluation, Preclinical Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications. Drug Screening,Evaluation Studies, Drug, Pre-Clinical,Drug Evaluation Studies, Preclinical,Drug Evaluations, Preclinical,Evaluation Studies, Drug, Preclinical,Evaluation, Preclinical Drug,Evaluations, Preclinical Drug,Medicinal Plants Testing, Preclinical,Preclinical Drug Evaluation,Preclinical Drug Evaluations,Drug Screenings,Screening, Drug,Screenings, Drug
D005822 Genetic Vectors DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition. Cloning Vectors,Shuttle Vectors,Vectors, Genetic,Cloning Vector,Genetic Vector,Shuttle Vector,Vector, Cloning,Vector, Genetic,Vector, Shuttle,Vectors, Cloning,Vectors, Shuttle
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000941 Antigens Substances that are recognized by the immune system and induce an immune reaction. Antigen
D001435 Bacteriophages Viruses whose hosts are bacterial cells. Phages,Bacteriophage,Phage
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining

Related Publications

R Cortese, and P Monaci, and A Luzzago, and C Santini, and F Bartoli, and I Cortese, and P Fortugno, and G Galfrè, and A Nicosia, and F Felici
July 1998, FEBS letters,
R Cortese, and P Monaci, and A Luzzago, and C Santini, and F Bartoli, and I Cortese, and P Fortugno, and G Galfrè, and A Nicosia, and F Felici
January 2003, Journal of receptor and signal transduction research,
R Cortese, and P Monaci, and A Luzzago, and C Santini, and F Bartoli, and I Cortese, and P Fortugno, and G Galfrè, and A Nicosia, and F Felici
February 2014, BMC biotechnology,
R Cortese, and P Monaci, and A Luzzago, and C Santini, and F Bartoli, and I Cortese, and P Fortugno, and G Galfrè, and A Nicosia, and F Felici
May 2012, Analytical biochemistry,
R Cortese, and P Monaci, and A Luzzago, and C Santini, and F Bartoli, and I Cortese, and P Fortugno, and G Galfrè, and A Nicosia, and F Felici
January 2012, Methods in molecular biology (Clifton, N.J.),
R Cortese, and P Monaci, and A Luzzago, and C Santini, and F Bartoli, and I Cortese, and P Fortugno, and G Galfrè, and A Nicosia, and F Felici
August 2017, Amino acids,
R Cortese, and P Monaci, and A Luzzago, and C Santini, and F Bartoli, and I Cortese, and P Fortugno, and G Galfrè, and A Nicosia, and F Felici
January 2008, Methods in enzymology,
R Cortese, and P Monaci, and A Luzzago, and C Santini, and F Bartoli, and I Cortese, and P Fortugno, and G Galfrè, and A Nicosia, and F Felici
June 2001, Enzyme and microbial technology,
R Cortese, and P Monaci, and A Luzzago, and C Santini, and F Bartoli, and I Cortese, and P Fortugno, and G Galfrè, and A Nicosia, and F Felici
March 1996, Nature medicine,
R Cortese, and P Monaci, and A Luzzago, and C Santini, and F Bartoli, and I Cortese, and P Fortugno, and G Galfrè, and A Nicosia, and F Felici
January 2001, Journal of immunological methods,
Copied contents to your clipboard!